Literature DB >> 18625251

Penn/VA center for studies of addiction.

Charles P O'Brien1, A Thomas McLellan, Anna Rose Childress, George E Woody.   

Abstract

The Penn/VA Center was founded in 1971 because of great concern over the number of Vietnam veterans returning home addicted to heroin. At that time little was known about the science of addiction, so our program from the very beginning was designed to gather data about the nature of addiction and measure the effects of available treatments. In other words, the goals were always a combination of treatment and research. This combination has continued to the present day. A human laboratory for the study of addiction phenomena such as conditioned responses was also founded in 1971. The key clinician investigators in this group have remained in the Center since the 1970s with most of the research staff continuing to work together. Important new investigators have been added over the years. Treatment was empirically based with randomized, controlled clinical trials as the gold standard for determining evidence-based treatment. The patients coming to treatment do not distinguish between abuse of alcohol and other drugs, so the treatment and research programs have always focused on all drugs including ethyl alcohol and the combination of ethyl alcohol with other drugs such as cocaine and opioids. Most of the patients coming for treatment also suffered from additional psychiatric disorders such as depression, anxiety, bipolar disorder or schizophrenia. Thus, the addiction treatment program in 1980 absorbed the rest of the VA Psychiatry Service into the Substance Abuse Program forming a new Behavioral Health Service with responsibility for over 9000 patients. The integration of substance abuse treatment with overall mental health care was the most efficient way to handle patients with complicated combinations of disorders. While this continues to be the best way to treat patients, it has proven difficult in practice. The main reason for this difficulty is that most mental health therapists whether they are psychiatrists, psychologists or social workers feel very inadequate to handle substance abuse problems. Unless they have had specialized training in addictive disorders, therapists are likely to be uncomfortable if substance abuse is one of the diagnoses while they may be quite comfortable treating other complex disorders such as schizophrenia. This lack of education of clinicians remains a major problem for our field. Some of the findings that came out of both the Penn/VA laboratory and clinical studies are now widely accepted and form the basis of standard clinical practice. These concepts and evidence will be briefly reviewed below.

Entities:  

Mesh:

Year:  2008        PMID: 18625251      PMCID: PMC3895091          DOI: 10.1016/j.neuropharm.2008.06.030

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  36 in total

Review 1.  Glutamatergic agents for cocaine dependence.

Authors:  Charles Dackis; Charles O'Brien
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

2.  Effects of buprenorphine and naloxone in morphine-stabilized opioid addicts.

Authors:  P J Fudala; E Yu; W Macfadden; C Boardman; C N Chiang
Journal:  Drug Alcohol Depend       Date:  1998-03-01       Impact factor: 4.492

3.  Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study.

Authors:  Charles A Dackis; Kevin G Lynch; Elmer Yu; Frederick F Samaha; Kyle M Kampman; James W Cornish; Amy Rowan; Sabrina Poole; Lenae White; Charles P O'Brien
Journal:  Drug Alcohol Depend       Date:  2003-05-01       Impact factor: 4.492

4.  Conditioned nalorphine-induced abstinence changes: persistence in post morphine-dependent monkeys.

Authors:  S R Goldberg; C R Schuster
Journal:  J Exp Anal Behav       Date:  1970-07       Impact factor: 2.468

5.  Predicting treatment response to naltrexone: the influence of craving and family history.

Authors:  J R Monterosso; B A Flannery; H M Pettinati; D W Oslin; M Rukstalis; C P O'Brien; J R Volpicelli
Journal:  Am J Addict       Date:  2001

6.  HIV risk reduction in the National Institute on Drug Abuse Cocaine Collaborative Treatment Study.

Authors:  George E Woody; Robert Gallop; Lester Luborsky; Jack Blaine; Arlene Frank; Ihsan M Salloum; David Gastfriend; Paul Crits-Christoph
Journal:  J Acquir Immune Defic Syndr       Date:  2003-05-01       Impact factor: 3.731

7.  Preliminary estimates of human immunodeficiency virus prevalence and incidence among cocaine abusers of Porto Alegre, Brazil.

Authors:  Flavio Pechansky; Lisia von Diemen; Felix Kessler; Vania Hirakata; David Metzger; George E Woody
Journal:  J Urban Health       Date:  2003-03       Impact factor: 3.671

Review 8.  Drug abuse treatment as AIDS prevention.

Authors:  D S Metzger; H Navaline; G E Woody
Journal:  Public Health Rep       Date:  1998-06       Impact factor: 2.792

9.  Naltrexone for heroin dependence treatment in St. Petersburg, Russia.

Authors:  Evgeny M Krupitsky; Edwin E Zvartau; Dimitry V Masalov; Marina V Tsoi; Andrey M Burakov; Valentina Y Egorova; Tatyana Y Didenko; Tatyana N Romanova; Eva B Ivanova; Anton Y Bespalov; Elena V Verbitskaya; Nikolai G Neznanov; Alexandr Y Grinenko; Charles P O'Brien; George E Woody
Journal:  J Subst Abuse Treat       Date:  2004-06

10.  A functional polymorphism of the mu-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients.

Authors:  David W Oslin; Wade Berrettini; Henry R Kranzler; Helen Pettinati; Joel Gelernter; Joseph R Volpicelli; Charles P O'Brien
Journal:  Neuropsychopharmacology       Date:  2003-06-18       Impact factor: 7.853

View more
  2 in total

Review 1.  Tales from the dark side: do neuromodulators of drug withdrawal require changes in endocannabinoid tone?

Authors:  Erik B Oleson; Roger Cachope; Aurelie Fitoussi; Joseph F Cheer
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-08-01       Impact factor: 5.067

2.  Diagnostic disagreements in bipolar disorder: the role of substance abuse comorbidities.

Authors:  Rowena Shalini Theodore; Monica Ramirez Basco; John R Biggan
Journal:  Depress Res Treat       Date:  2012-01-26
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.